Table 2.
Prevalence of long-term antipsychotic polypharmacy combinations (n = 338)
| Antipsychotic medication | n | Plus at least one other FGAa n (%) | Plus at least one other SGAa n (%) |
|---|---|---|---|
| First Generation Antipsychotics (FGA)a | |||
| Chlorpromazine | 8 | 1 (12.5) | 7 (87.5) |
| Flupentixol | 26 | 6 (23.1) | 20 (76.9) |
| Fluphenazine | 4 | 2 (50.0) | 2 (50.0) |
| Haloperidol | 30 | 5 (16.7) | 25 (83.3) |
| Levomepromazine | 1 | - | 1 (100.0) |
| Pericyazine | 1 | 1 (100.0) | - |
| Pimozide | 2 | - | 2 (100.0) |
| Pipothiazine | 10 | 2 (20.0) | 8 (80.0) |
| Sulpride | 33 | 1 (3.0) | 32 (97.0) |
| Trifluoperazine | 3 | - | 3 (100.0) |
| Zuclopenthixol | 25 | - | 25 (100.0) |
| Second Generation Antipsychotics (SGA)a | |||
| Amisulpride | 118 | 18 (15.3) | 100 (84.7) |
| Aripiprazole | 79 | 12 (15.2) | 67 (84.8) |
| Clozapine | 168 | 27 (16.1) | 141 (83.9) |
| Olanzapine | 95 | 44 (46.3) | 51 (53.7) |
| Paliperidone | 40 | 8 (20.0) | 32 (80.0) |
| Quetiapine | 21 | 11 (52.4) | 10 (47.6) |
| Risperidone | 64 | 21 (32.8) | 43 (67.2) |
aThese are overlapping categories; antipsychotic combinations may include additional FGAs or SGA where patients are prescribed more than 2 antipsychotics simultaneously